Company Analysis Intercept Pharmaceuticals
1. Summary
Advantages
- Price (19 $) is less than fair price (22.33 $)
- The stock's return over the last year (0%) is higher than the sector average (-30.44%).
- Current debt level 60.09% is below 100% and has decreased over 5 years from 72.91%.
Disadvantages
- Dividends (0%) are below the sector average (0.5442%).
- The company's current efficiency (ROE=-253.45%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Intercept Pharmaceuticals | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -20.1% | -0.3% |
| 90 days | 0% | -34.3% | 8.1% |
| 1 year | 0% | -30.4% | 30.1% |
ICPT vs Sector: Intercept Pharmaceuticals has outperformed the "Healthcare" sector by 30.44% over the past year.
ICPT vs Market: Intercept Pharmaceuticals has significantly underperformed the market by -30.12% over the past year.
Stable price: ICPT is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ICPT with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (19 $) is lower than the fair price (22.33 $).
Price not significantly lower than the fair price: The current price (19 $) is slightly lower than the fair price by 17.5%.
4.2. P/E
P/E vs Sector: The company's P/E (3.48) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (3.48) is lower than that of the market as a whole (48.79).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.3) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (4.3) is higher than that of the market as a whole (3.36).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.4) is lower than that of the sector as a whole (33.76).
P/S vs Market: The company's P/S indicator (1.4) is lower than that of the market as a whole (10.23).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-11.06) is higher than that of the sector as a whole (-22.15).
EV/Ebitda vs Market: The company's EV/Ebitda (-11.06) is lower than that of the market as a whole (28.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -26.68% over the last 5 years.
Accelerating profitability: The return for the last year (5.62%) exceeds the average return for 5 years (-26.68%).
Profitability vs Sector: The return for the last year (5.62%) exceeds the return for the sector (-9.16%).
5.4. ROE
ROE vs Sector: The company's ROE (-253.45%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-253.45%) is lower than that of the market as a whole (10.82%).
5.5. ROA
ROA vs Sector: The company's ROA (21.31%) is higher than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (21.31%) is higher than that of the market as a whole (6.51%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5442%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
